Filing Overview
This Form 6-K was filed on September 4, 2020, by I-MAB, a foreign private issuer headquartered in Shanghai, China, for the month of September 2020. The filing identifies I-MAB as the registrant; the request metadata names Novabridge Biosciences, which is not reflected in the filing text.
Financial and Operating Information
The provided filing text contains only the Form 6-K cover page and an exhibit index. It does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes and Outlook
The filing text does not describe changes versus a prior comparable period, guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Investor Verification Items
- Verify the issuer identity, because the filing names I-MAB rather than Novabridge Biosciences.
- Review Exhibit 99.1, identified as a press release, for the substantive disclosure; its contents are not included in the provided text.
- Confirm whether the September 4, 2020 filing contains any financial, clinical, corporate, or market disclosures in the omitted exhibit.
- Note that I-MAB indicated it files annual reports on Form 20-F.